carmustine has been researched along with Optic Nerve Diseases in 3 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Optic Nerve Diseases: Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The syndrome of retinal vascular occlusion, optic neuropathy, and myelopathy is associated with the high-dose chemotherapeutic agents carmustine and cisplatin." | 7.70 | Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. ( Arnold, AC; Glasgow, BJ; Vinters, HV; Wang, MY, 2000) |
| "The syndrome of retinal vascular occlusion, optic neuropathy, and myelopathy is associated with the high-dose chemotherapeutic agents carmustine and cisplatin." | 3.70 | Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. ( Arnold, AC; Glasgow, BJ; Vinters, HV; Wang, MY, 2000) |
| "Nine patients with advanced breast cancer were referred for visual symptoms after high-dose chemotherapy with cisplatin, cyclophosphamide, and carmustine and autologous bone marrow transplantation without total body irradiation or local head irradiation." | 3.69 | Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. ( Jaffe, GJ; Khawly, JA; Peters, WP; Petros, W; Rubin, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khawly, JA | 1 |
| Rubin, P | 1 |
| Petros, W | 1 |
| Peters, WP | 1 |
| Jaffe, GJ | 1 |
| Shuper, A | 1 |
| Horev, G | 1 |
| Kornreich, L | 1 |
| Michowiz, S | 1 |
| Weitz, R | 1 |
| Zaizov, R | 1 |
| Cohen, IJ | 1 |
| Wang, MY | 1 |
| Arnold, AC | 1 |
| Vinters, HV | 1 |
| Glasgow, BJ | 1 |
3 other studies available for carmustine and Optic Nerve Diseases
| Article | Year |
|---|---|
Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1996 |
Visual pathway glioma: an erratic tumour with therapeutic dilemmas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 1997 |
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Breast Neoplasms; Carcinoma, Ductal, Brea | 2000 |